Fei li, PhD

The First Affiliated Hospital of Nanchang University, China (People's Republic)

N/A

Poster(s):

• 1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

• 1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)